Fc Engineered Anti-Human RSV Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ28] (CAT#: BioBet-C028ZP) Datasheet

Target
RSV
Isotype
Whole Humanized Antibody
Description
CDC-Enhanced Palivizumab is a Fc-modified anti-RSV therapeutic biobetter antibody. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Palivizumab, Palivizumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Infections, Respiratory Syncytial Virus
Classification
Therapeutic antibody; biobetter
Patent
Blinatumomab was first received FDA approval in 2000. The patent expired in the United States in 2015.
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Palivizumab . For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
RSV
Full Name
cytotoxic T-lymphocyte associated protein 4
Background
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.
Alternative Names
CD; GSE; GRD4; ALPS5; CD152; RSV; IDDM12; CELIAC3
Gene ID
UniProt ID
Trade name
Synagis
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB00110 (BTD00097, BIOD00097)
CAS number
188039-54-5
Antibody Isotype
Whole Humanized Antibody
Description
Palivizumab is a humanized monoclonal antibody (IgG) that targets the epitope of the RSV F protein A antigenic site. It is used to prevent respiratory syncytial virus (RSV) infection. Palizumab was approved for medical use in 1998.
Indication
Infections, Respiratory Syncytial Virus
Synonyms
Palivizumab
UNII
DQ448MW7KS

Palivizumab binds to RSV's fusion glycoprotein and inhibits its entry into cells, thereby preventing it from being bound and taken up by host cell receptors. Studies show that Palivizumab has the ability to induce significant response for ADCC.

Infections, Respiratory Syncytial Virus

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK